Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the … – Nasdaq
High Point Observer |
Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the …
Nasdaq NEW YORK and CLEVELAND, May 02, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, … Abeona Therapeutics (ABEO) Provides Update from Ongoing Phase 1/2 Trial of EB-101 Gene Therapy for Severe Form … Abeona Therapeutics Inc (ABEO) Earns Buy Rating from Jefferies Group LLC $-0.06 EPS Expected for ARC Group WorldWide (ARCW); Abeona Therapeutics (ABEO) Shorts Up By 2.53% |
